Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
... today at the XXII International Society on thrombosis
and Haemostasis Congress in Boston. Edoxaban is ... established by the International Society on thrombosis
and Haemostasis(3), the most sensitive scale of ... products in non-surgical patients. Journal of thrombosis
and Haemostasis 2005;3: 692-694.
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
... being developed for the prevention of deep vein thrombosis
orthopaedic surgery. The decision ... the XXII
Congress of the International Society on thrombosis
and Haemostasis (ISTH) on
July 15, 2009 in ... this product candidate."
About Deep Vein thrombosis
DVT is caused when a blood clot ...
Isis and Collaborators Present New Research at the ATVB Annual Conference
... data were presented during the Arteriosclerosis, thrombosis
and Vascular Biology's (ATVB) Annual Conference. ... drug candidate for development from our new thrombosis
effort. It is another example of the power of ... Factor XI as the optimal target to inhibit thrombosis
without causing bleeding. In addition to Factor ...
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
... for TAXUS, p-value=0.092)*.
No stent thrombosis
between two and three years with XIENCE V, and a low rate of stent thrombosis
from zero to three years, per Academic Research ... (ARC) definition of definite/probable stent thrombosis
(0.9 percent for XIENCE V and 2.8 percent for ...
March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots
... flights aren't the only risk factor for deep vein thrombosis
(DVT), the medical term for blood clots in the ...
For most healthy adults, deep vein thrombosis
is extremely rare. Every year, about 350,000 ... are used to diagnose DVT. Treatment for deep vein thrombosis
seeks to prevent the clot from becoming bigger ...
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
-- Low rates of stent thrombosis
(blood clotting within the treated area)
per the ... (ARC) definition of definite/probable
(1.3 percent for XIENCE V vs. 1.7 percent for ... percent for TAXUS).
The ARC definitions of stent thrombosis
were developed to eliminate
variability in the ...
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
important anti-platelet therapy in treating thrombosis
patients in both the
acute and chronic settings." ... receptor on
platelets has been proven to prevent thrombosis
and subsequent heart attacks.
Portola believes ... ischemic events, and elective PCI.
Thrombosis, or the development of harmful ...
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
... arterial thromboembolic events (i.e., deep-vein thrombosis
of the lower and upper limbs, visceral and ... i n the Treat m ent of Deep-Venous thrombosis
(EQUINOX Study): Safety, Efficacy, and ... patients with symptomatic and confirmed deep-vein thrombosis
were randomized to receive weekly subcutaneous ...
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
... receptor on platelets has been proven to prevent thrombosis
subsequent heart attacks. Portola believes ... of Cardiovascular Research at the
Center for thrombosis
Research at Sinai Hospital, Baltimore, MD. ... achieved the
predefined endpoint. Inhibition of thrombosis
was highly significant in
these non-responder ...
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
... TAXUS, p-value=0.03)*.
-- Low rates of stent thrombosis
between one and two years, defined as
very late ... (ARC)
definition of definite/probable stent thrombosis
(0.5 percent for XIENCE V
and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis
developed to eliminate variability in the ...
Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent
... The adjusted rate of ARC
definite/probable stent thrombosis
at three years for the TAXUS Liberte
Stent group ... adjusted rate of ARC
definite/probable stent thrombosis
for the direct stent group at 0.3
percent, as ... of 46 percent. ARC definite/probable total
at two years was 0.8 percent for the TAXUS ...
APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism
... MPH to reduce the number of
cases of deep vein thrombosis
and pulmonary embolism in the United States.
... Pulmonary Section, blood clots, called deep vein thrombosis
occur after periods of being immobile, ... and prevention of symptomless deep-vein thrombosis
flights: a randomised trial. Lancet. ...
Surgeon General's 'Call to Action' to Prevent DVT/PE Praised by NATT as Turning Point
... -- The National
Alliance for thrombosis
and Thrombophilia (NATT) praised Acting ... to Action" (CTA) to prevent deep vein thrombosis
(DVT) and pulmonary
RADM Galson ... NC
In the past year, CDC has designated thrombosis
as a priority,
increasing surveillance of DVT/PE ...
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
... re-intervention (TLR) (2.5%). The definite
rate was 0.8 percent after one year, which is ... stent-related composite cardiac events
and stent thrombosis
were 4.3 percent and 0.9 percent respectively. ... "The low
occurrence of cardiac events and stent thrombosis
is noteworthy, especially
given the high degree ...
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
risk of heart attack and stent thrombosis
compared with clopidogrel among ... was also a
significantly lower rate of stent thrombosis
among diabetes patients
treated with prasugrel, ... in a 48 percent relative risk reduction
in stent thrombosis
compared with clopidogrel (3.6 percent vs. 2.0 ...
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
... peripheral conditions related to arterial thrombosis
with a novel
mechanism that may provide ... novel mechanism of
is the formation of a clot, or thrombus, inside a ... and efficacy of APD791; the role of
serotonin in thrombosis
and in increasing cardiovascular risk; how ...
Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women
... the prevention and management of thrombosis
in key patient
populations and reinforce ... on the challenges in preventing and treating thrombosis
pregnant women and children, and on managing ... are used to prevent and treat thrombosis
or blood clotting that
arises in arteries, veins, ...
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
... Long-Term Clinical Outcomes, Lower Rates of Stent thrombosis
than Patients Treated ... lower observed rates of late and very late stent thrombosis
XIENCE V-treated patients, especially in those ... for TAXUS, p-value=0.07)*. -- Low rates of stent thrombosis
between one and two years, defined as very ...
TRITON-TIMI 38 Stent Analysis Favors Prasugrel
... since the stenting
procedure, or the way stent thrombosis
The results of the TRITON-TIMI 38 ... Overall,
prasugrel reduced both early stent thrombosis
-- within 30 days of stenting
-- when compared ... hazard
ratio 0.41, p<0.001) -- and late stent thrombosis
-- more than 30 days
after stenting (0.49 percent ...
Study Finds Repeated Episodes of Stent Thrombosis Common
... Treating stent thrombosis
with another stent hikes the risk of repeat blood ... attack or even death. A single incident of stent thrombosis
enough, but a new study suggests that one ... total of 437 consecutive patients who had stent thrombosis
angiography between January 2004 and ...
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
... both BMS and DES at the time of enrollment. Stent thrombosis
pre-defined secondary endpoint in the ... reduced the relative risk of coronary stent thrombosis
clot at the implanted stent site) over ... research consortium (ARC)
definition of stent thrombosis
was used - definite/confirmed stent
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
... Continued to Be Associated with
Reductions in thrombosis
and Improvements in Fatigue, Quality of Life, and ... was
associated with sustained reduction in thrombosis
and improvements in
fatigue, overall quality of ... in
Transfusion Requirements, Fatigue and thrombosis
with Eculizumab Treatment
in Paroxysmal Nocturnal ...
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
... (NYSE: SGP ) and The Sinai Center for thrombosis
Sinai Hospital of Baltimore today ... Paul Gurbel, MD, Director of The Sinai
Center for thrombosis
Research, Sinai Hospital of Baltimore; ... Blood work
was processed at The Sinai Center for thrombosis
Research and the
University of Oklahoma Health ...
Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
... rates of death,
myocardial infarction, and stent thrombosis
across a broad cross section of
patients and lesions and with no new cases of stent thrombosis
years four and five," said Gregg W. ... the TAXUS
IV trial reported no cases of stent thrombosis
between years four and five
for the TAXUS Stent ...
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
... a difference in either acute (30 day) or late thrombosis
rates between XIENCE V and TAXUS out to one year. ... a statistical difference between rates of
for XIENCE V or TAXUS out to one year in the SPIRIT III
trial. Rates of late stent thrombosis
at one year per protocol were 0.3
percent for ...
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
reported the overall incidence of stent thrombosis
in the data set using
the Academic Research ... and definite/probable/possible stent thrombosis
the CYPHER(R) Stent at three years were ... 5.3 percent and 6.4
percent, respectively. Stent thrombosis
comparisons between the CYPHER(R)
Stent and the ...
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
... the REALITY Trial
investigators reported a stent thrombosis
rate for the Taxus Stent that was
significantly ... the difference between the
protocol-defined stent thrombosis
rate for each drug-eluting stent in the
diabetic ... death, Q-wave myocardial
infarction and stent thrombosis
favoring the CYPHER(R) Stent were also seen
Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
... the bare-metal control
experienced one stent thrombosis
during this same period. This marks the
third consecutive year of TAXUS II follow-up with no stent thrombosis
in the TAXUS stent patient group. The ... data regarding late and
very late stent thrombosis
out to five years," said Prof. Sigmund ...
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
... difference between their rates of stent thrombosis
clots). "The five-year results of the ... a significant difference in
the rates of stent thrombosis
between the CYPHER(R) Stent and the bare
metal ... were used,
the rates of acute and subacute stent thrombosis
were 0.0 percent for the
bare metal stent and 1.1 ...
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
... that Soliris substantially
reduced the risk of thrombosis
in a diverse population of PNH ... the course of the disease.(3,4,5,6) An initial thrombosis
the relative risk of death by five- to ... hemolysis in all treated
patients and reduced thrombosis
by 92 percent, with three events during
Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study
... a history of blood clots helps to prevent a condition known as deep-vein thrombosis
or to improve other clinical outcomes.
The report, a summary of which ...
As many as 600,000 Americans each year may have deep-vein thrombosis
-- blood clots that form in the legs or pelvis. The condition occurs most ...
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
... Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis
rate for Taxus treated patients increased from one to two years from 4.2% ... at 658 days in a patient who had previously presented with a subacute thrombosis
and who was on dual antiplatelet therapy at the time of both thromboses. ...
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
... or its components, including death, repeat heart attack, stroke or stent thrombosis
at one year.
"The HORIZONS AMI trial provided outcomes data showing ... individual rates of death, repeat heart attack, stroke and stent thrombosis
between the two groups through 12 months of follow-up, which persisted ...
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
... blood. Platelets serve a central role in forming pathological arterial thrombosis
that causes myocardial infarction and stroke. The study's authors further ... to identify postmenopausal women with an increased risk of arterial thrombosis
or clotting before even starting estrogen therapy is an important goal to ...
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
... that the device was absorbed. In addition, there were no cases of thrombosis
(blood clot formation) out to two years of follow-up, and no new major ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis
rates - at 30 days; six, nine, 12 and 18 months; and two years, with ...
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
... the following key results:
A zero percent rate of stent thrombosis
(blood clot formation) for all patients out to two years of follow up.
... Key endpoints of the study include assessments of safety - MACE and stent thrombosis
rates - at 30 days, six, nine and 18 months, and one and two years, with ...
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
... option," said Richard Becker, MD, director of the Duke Cardiovascular thrombosis
Center and lead author of the study. "TRA appears to work in a novel way ... which demonstrate the potential to address unmet medical needs.
may result in partial or complete blockage of arteries in the heart, brain ...
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
... evaluated using guidelines established by
the International Society on thrombosis
and Haemostasis(1), the most sensitive
scale of those currently used in ... of antihemostatic medicinal products in non-surgical patients.
Journal of thrombosis
and Haemostasis 2005;3: 692-694.
2. Jorgensen, H.S., Nakayama, ...
Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
... were a target lesion revascularization (TLR) rate of 5%, a
(SAT) rate of 0.4%, a late stent thrombosis
of 0.3%, and a major adverse cardiac events (MACE) rate of ....
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
... follow-up data from the ATLANTA Trial. The results include zero
in patients discontinuing dual anti-platelet therapy
after only 30 days.
... FIM patient population, the
results showed zero (0.0) percent stent thrombosis
Consortium, or ARC-defined), death, myocardial ...